• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

TriSalus releases positive data for its catheter-based drug delivery tech

November 21, 2022 By Sean Whooley

Trisalus pressure enabled drug delivery (PEDD) system
TriSalus is focused on a pressure-enabled drug delivery (PEDD) system [Image from TriSalus website]
TriSalus Life Sciences today announced positive clinical results for its Pressure-Enabled Regional Immuno-Oncology technology.

The company, currently in the process of going public through a SPAC merger, filed a presentation for investors. It features information regarding its ongoing PERIO 01 and PERIO 02 clinical studies. The studies evaluate the TriNav pressure-enabled drug delivery technology for primary and metastatic liver tumors. It delivers SD-101, a class C toll-like receptor 9 (TLR9) agonist.

Last week, TriSalus announced plans to go public through a merger with MedTech Acquisition Corp., a special purpose acquisition company (SPAC).

“We are commercializing our TriNav infusion system and developing SD-101 to potentially enable more patients with liver and pancreatic tumors to benefit from immunotherapeutics and the current standard of care,” said Mary Szela, president and CEO of TriSalus. “Today we are providing recent clinical data from our SD-101 studies so investors can better understand the progress to date and the potential upside that our company can generate.”

About TriSalus’ presentation

In the presentation, TriSalus shared data demonstrating consistency with the hypothesis that TriNav can achieve high SD-101 levels in the liver. It does so with limited systemic exposure using the PEDD method. SD-101 delivered with TriNav also offers evidence of induction of immunostimulatory cytokines in the blood. It demonstrated reductions in liver tumor monocytic myeloid-derived suppressor cells (MDSC) levels.

To date, 27 patients received treatment with 123 infusions of SD-101 in the PERIO trials. None experienced serious cytokine adverse events related to SD-101. Additionally, none reported serious adverse events related to the TriNav or PEDD technologies.

TriSalus expects Phase 1 response data from the trials next month. It plans to continue to enroll at higher SD-101 dose levels in combination with checkpoint inhibitors.

“The initial findings from these studies offer encouraging data supporting TriSalus’ proprietary [PEDD] method,” said Dr. Steven C. Katz, CMO at TriSalus. “This promising clinical data demonstrate that SD-101 delivered via TriNav may support broad immune effects in liver tumors and eliminate [MDSC]. Importantly, the data further substantiates the potential of our therapeutic platform to significantly improve immunotherapy outcomes for patients with liver and pancreatic tumors.”

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Mergers & Acquisitions, Oncology Tagged With: trisaluslifesciences

IN CASE YOU MISSED IT

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS